161814-49-9 | (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$45.00	$31.00
25mg	98%	in stock	$92.00	$64.00
100mg	98%	in stock	$186.00	$130.00
250mg	98%	in stock	$283.00	$198.00
1g	98%	in stock	$746.00	$522.00

Description

• Catalog Number: AA87802
• Chemical Name: (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate
• CAS Number: 161814-49-9
• Molecular Formula: C25H35N3O6S
• Molecular Weight: 505.6269
• MDL Number: MFCD00934214
• SMILES: CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)O)C

Computed Properties

• Complexity: 745
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 12
• XLogP3: 2.9

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

  Journal of virology 20140301

• GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

  Antimicrobial agents and chemotherapy 20131201

• P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.

  Antimicrobial agents and chemotherapy 20131001

• Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.

  Chemistry & biology 20130919

• Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20130912

• GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20130501

• In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.

  The Journal of antimicrobial chemotherapy 20130101

• Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.

  Journal of virology 20130101

• Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.

  PloS one 20130101

• Role of FAP48 in HIV-associated lipodystrophy.

  Journal of cellular biochemistry 20121101

• Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

  Antimicrobial agents and chemotherapy 20121101

• The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes.

  AIDS (London, England) 20121023

• NMR study of xenotropic murine leukemia virus-related virus protease in a complex with amprenavir.

  Biochemical and biophysical research communications 20120824

• Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization.

  Journal of medicinal chemistry 20120809

• Molecular and enzymatic characterization of XMRV protease by a cell-free proteolytic analysis.

  Journal of proteomics 20120803

• Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20120726

• Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization.

  Journal of medicinal chemistry 20120726

• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  Journal of medicinal chemistry 20120614

• Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

  AIDS (London, England) 20120601

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Use of the cassette-dosing approach to assess brain penetration in drug discovery.

  Drug metabolism and disposition: the biological fate of chemicals 20120501

• HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.

  The Journal of antimicrobial chemotherapy 20120501

• Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.

  Biopharmaceutics & drug disposition 20120501

• Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

  Pharmaceutical research 20120401

• Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.

  Protein science : a publication of the Protein Society 20120301

• Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.

  Bioorganic & medicinal chemistry letters 20120301

• Exploring the complexity of the HIV-1 fitness landscape.

  PLoS genetics 20120301

• In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.

  Pharmaceutical research 20120201

• Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.

  Journal of computer-aided molecular design 20120201

• Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.

  Journal of medicinal chemistry 20120112

• Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20120101

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

  PloS one 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs.

  In vivo (Athens, Greece) 20120101

• Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation.

  International journal of nanomedicine 20120101

• Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein.

  PloS one 20120101

• Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.

  International journal of molecular sciences 20120101

• Computable features required to evaluate the efficacy of drugs and a universal algorithm to find optimally effective drug in a drug complex.

  PloS one 20120101

• Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.

  Retrovirology 20120101

• Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles.

  PloS one 20120101

• Novel therapeutic strategies targeting HIV integrase.

  BMC medicine 20120101

• HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

  International journal of hepatology 20120101

• Nanoparticle-mediated targeted delivery of antiretrovirals to the brain.

  Methods in enzymology 20120101

• Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs.

  Alcoholism, clinical and experimental research 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Diagnosis & treatment of tuberculosis in HIV co-infected patients.

  The Indian journal of medical research 20111201

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

  The FEBS journal 20111101

• Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.

  Hormone research in paediatrics 20111101

• Elucidating the energetics of entropically driven protein-ligand association: calculations of absolute binding free energy and entropy.

  The journal of physical chemistry. B 20111020

• Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors.

  Journal of pharmaceutical sciences 20110901

• Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.

  Journal of medicinal chemistry 20110825

• Evaluation of antifungal activity of medicinal plant extracts against oral Candida albicans and proteinases.

  Mycopathologia 20110801

• The progress made in determining the Mycobacterium tuberculosis structural proteome.

  Proteomics 20110801

• Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).

  HIV medicine 20110801

• The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

  Antimicrobial agents and chemotherapy 20110601

• SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

  PLoS neglected tropical diseases 20110601

• (3aR,6S,7aR)-7a-Bromo-2-methyl-sulfonyl-1,2,3,6,7,7a-hexa-hydro-3a,6-ep-oxy-isoindole.

  Acta crystallographica. Section E, Structure reports online 20110601

• Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.

  HIV medicine 20110501

• Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor.

  Journal of fluorescence 20110501

• Human immunodeficiency virus therapeutics and pharmacogenomics.

  Indian journal of human genetics 20110501

• Proper laboratory notebook practices: protecting your intellectual property.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401

• Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

  Antimicrobial agents and chemotherapy 20110401

• Clinical applications of drug desensitization in the Asia-Pacific region.

  Asia Pacific allergy 20110401

• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  Journal of pharmaceutical and biomedical analysis 20110325

• The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.

  Memorias do Instituto Oswaldo Cruz 20110301

• Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110201

• Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

  The Journal of antimicrobial chemotherapy 20110201

• Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

  Journal of medicinal chemistry 20110127

• Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

  AIDS research and therapy 20110101

• Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series.

  Radiation oncology (London, England) 20110101

• Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1.

  Virology journal 20110101

• Machine learning on normalized protein sequences.

  BMC research notes 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.

  Breast cancer : basic and clinical research 20110101

• HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

  The open medicinal chemistry journal 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101

• Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.

  PloS one 20110101

• Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

  PloS one 20110101

• Preventive fluid and dietary therapy for urolithiasis: An appraisal of strength, controversies and lacunae of current literature.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.

  Journal of pharmacology & pharmacotherapeutics 20110101

• Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.

  PloS one 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Human immunodeficiency virus endocrinopathy.

  Indian journal of endocrinology and metabolism 20110101

• Antiviral mode of action of bovine dialyzable leukocyte extract against human immunodeficiency virus type 1 infection.

  BMC research notes 20110101

• Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.

  PloS one 20110101

• Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

  Retrovirology 20110101

• A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.

  BMC bioinformatics 20110101

• Pharmacokinetics of dl-praeruptorin A after single-dose intravenous administration to rats with liver cirrhosis.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma.

  Indian journal of pharmaceutical sciences 20110101

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.

  ChemMedChem 20101108

• HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.

  Journal of molecular and cellular cardiology 20101101

• Inhibiting the gastric burst release of drugs from enteric microparticles: the influence of drug molecular mass and solubility.

  Journal of pharmaceutical sciences 20101101

• Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.

  Cancer chemotherapy and pharmacology 20101101

• Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.

  Circulation 20101101

• Molecular Basis for Drug Resistance in HIV-1 Protease.

  Viruses 20101101

• Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease.

  Journal of molecular modeling 20101001

• Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20101001

• HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.

  Journal of pharmaceutical and biomedical analysis 20100905

• Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

  Analytical and bioanalytical chemistry 20100901

• Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.

  The FEBS journal 20100901

• Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.

  Drug metabolism and disposition: the biological fate of chemicals 20100801

• Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20100801

• A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

  Archives of internal medicine 20100726

• A medicinal chemist's guide to molecular interactions.

  Journal of medicinal chemistry 20100722

• Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling.

  Biopharmaceutics & drug disposition 20100701

• Role of Gag in HIV Resistance to Protease Inhibitors.

  Viruses 20100701

• Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601

• Mass spectrometry and renal calculi.

  Journal of medicine and life 20100515

• Electrochemical evaluation and determination of antiretroviral drug fosamprenavir using boron-doped diamond and glassy carbon electrodes.

  Analytical and bioanalytical chemistry 20100501

• Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.

  Journal of virology 20100501

• Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.

  Archives of toxicology 20100401

• Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method.

  Bioanalysis 20100401

• Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.

  HIV medicine 20100301

• Multiple effects of amprenavir against Candida albicans.

  FEMS yeast research 20100301

• Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.

  Biopharmaceutics & drug disposition 20100301

• Dosage and formulation issues: oral vitamin E therapy in children.

  European journal of clinical pharmacology 20100201

• Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.

  Bioorganic & medicinal chemistry letters 20100201

• HIV protease inhibitors block oral epithelial cell DNA synthesis.

  Archives of oral biology 20100201

• HIV Genetic Diversity and Drug Resistance.

  Viruses 20100201

• HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

  Gastroenterology 20100101

• Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.

  Journal of molecular graphics & modelling 20100101

• The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

  British journal of pharmacology 20100101

• Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.

  The open AIDS journal 20100101

• Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.

  PloS one 20100101

• Profile of etravirine for the treatment of HIV infection.

  Therapeutics and clinical risk management 20100101

• Abacavir/lamivudine combination in the treatment of HIV: a review.

  Therapeutics and clinical risk management 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.

  Antiviral therapy 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.

  Antiviral therapy 20100101

• An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells.

  PloS one 20100101

• Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.

  PloS one 20100101

• Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.

  PloS one 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.

  PloS one 20100101

• Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.

  Retrovirology 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

  Antiviral therapy 20100101

• Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20091210

• Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

  Therapeutic drug monitoring 20091201

• HIV-1 Protease: Structural Perspectives on Drug Resistance.

  Viruses 20091201

• Mutation rates and intrinsic fidelity of retroviral reverse transcriptases.

  Viruses 20091201

• Current and Novel Inhibitors of HIV Protease.

  Viruses 20091201

• Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.

  Biochemical and biophysical research communications 20091113

• How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.

  AIDS (London, England) 20091113

• Antiretroviral compounds and cholesterol efflux from macrophages.

  Atherosclerosis 20091001

• The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.

  Journal of acquired immune deficiency syndromes (1999) 20091001

• A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

  Journal of acquired immune deficiency syndromes (1999) 20090901

• Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

  The Journal of antimicrobial chemotherapy 20090801

• Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.

  Pharmacotherapy 20090801

• Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20090709

• Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.

  Journal of chemical information and modeling 20090701

• Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090628

• Effectiveness of commercial inhibitors against subtype F HIV-1 protease.

  Journal of enzyme inhibition and medicinal chemistry 20090601

• Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

  The Journal of antimicrobial chemotherapy 20090601

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

  Antiviral research 20090501

• Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.

  Journal of medicinal chemistry 20090423

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• Predicting drug resistance of the HIV-1 protease using molecular interaction energy components.

  Proteins 20090301

• GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

  Antimicrobial agents and chemotherapy 20090301

• Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.

  Antimicrobial agents and chemotherapy 20090301

• Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.

  The Journal of antimicrobial chemotherapy 20090301

• Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.

  PLoS pathogens 20090301

• Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

• Role of NEDD8 in HIV-associated lipodystrophy.

  Differentiation; research in biological diversity 20090201

• Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

  Clinical chemistry 20090101

• Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

  PPAR research 20090101

• Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.

  Retrovirology 20090101

• Darunavir: a review of its use in the management of HIV infection in adults.

  Drugs 20090101

• HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis.

  PloS one 20090101

• Is PPARγ a prospective player in HIV-1-associated bone disease?

  PPAR research 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

  Journal of the International AIDS Society 20090101

• Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).

  HIV clinical trials 20090101

• The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study.

  Interdisciplinary perspectives on infectious diseases 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.

  BMC bioinformatics 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models.

  Diabetology & metabolic syndrome 20090101

• Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy.

  Journal of biomedicine & biotechnology 20090101

• The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review.

  BMC public health 20090101

• Hepatic profile analyses of tipranavir in Phase II and III clinical trials.

  BMC infectious diseases 20090101

• Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.

  AIDS research and therapy 20090101

• Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

  Core evidence 20090101

• Profile of darunavir in the management of treatment-experienced HIV patients.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Role of darunavir in the management of HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.

  Drug metabolism and disposition: the biological fate of chemicals 20081201

• PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.

  Journal of medical virology 20081201

• Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.

  Therapeutics and clinical risk management 20081201

• Evolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypes.

  PLoS computational biology 20081101

• Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy.

  Annals of neurology 20081101

• Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.

  Journal of medicinal chemistry 20081023

• Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.

  Organic & biomolecular chemistry 20081021

• Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility.

  Statistics in medicine 20081015

• Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20081009

• Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).

  Biochemical pharmacology 20081001

• Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.

  Current medicinal chemistry 20081001

• [Chemical characteristics, mechanism of action and antiviral activity of darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

  Therapeutics and clinical risk management 20081001

• Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.

  Bioorganic & medicinal chemistry 20080915

• Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.

  Journal of medicinal chemistry 20080814

• Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.

  Therapeutic drug monitoring 20080801

• Synthesis and biological evaluation of novel isopropanolamine derivatives as non-peptide human immunodeficiency virus protease inhibitors.

  Chemical & pharmaceutical bulletin 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• Combating HIV resistance - focus on darunavir.

  Therapeutics and clinical risk management 20080801

• Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.

  Journal of virological methods 20080701

• Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.

  Pharmacotherapy 20080701

• [Pneumococcal conjugate vaccine failure in HIV-infected child. Clinical case].

  Anales de pediatria (Barcelona, Spain : 2003) 20080701

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• Atriplatrade mark - HIV therapy in one pill.

  Therapeutics and clinical risk management 20080601

• Evaluating the potency of HIV-1 protease drugs to combat resistance.

  Proteins 20080515

• HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

  Journal of the American Chemical Society 20080514

• Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.

  Cancer biology & therapy 20080501

• Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

  Antimicrobial agents and chemotherapy 20080501

• Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• Inhibitory quotient in HIV pharmacology.

  Current opinion in HIV and AIDS 20080501

• Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.

  Journal of computational chemistry 20080415

• Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

  Antimicrobial agents and chemotherapy 20080401

• Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

  Chemical biology & drug design 20080401

• Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.

  Biopharmaceutics & drug disposition 20080301

• In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.

  Drug metabolism and disposition: the biological fate of chemicals 20080301

• Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301

• [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].

  Enfermedades infecciosas y microbiologia clinica 20080301

• Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.

  Drug metabolism and disposition: the biological fate of chemicals 20080201

• Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20080201

• Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.

  Fundamental & clinical pharmacology 20080201

• Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.

  AIDS (London, England) 20080130

• Response to 'key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients'.

  AIDS (London, England) 20080102

• HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.

  Trends in pharmacological sciences 20080101

• Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.

  Pharmacotherapy 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

  BMC infectious diseases 20080101

• Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.

  Retrovirology 20080101

• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

  AIDS research and therapy 20080101

• Proteochemometric modeling of HIV protease susceptibility.

  BMC bioinformatics 20080101

• Same patient, new stone composition: amprenavir urinary stone.

  Antiviral therapy 20080101

• Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.

  BMC infectious diseases 20080101

• Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy.

  BMC medical research methodology 20080101

• [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency].

  Medecine et maladies infectieuses 20071201

• Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.

  AIDS patient care and STDs 20071201

• Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.

  AIDS (London, England) 20071130

• HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115

• HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.

  Atherosclerosis 20071101

• Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition.

  Clinical and vaccine immunology : CVI 20071101

• Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.

  The Journal of antimicrobial chemotherapy 20071101

• Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

  Clinical therapeutics 20071101

• Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.

  AIDS (London, England) 20071018

• Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.

  Pharmaceutical research 20071001

• Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

  The Journal of antimicrobial chemotherapy 20071001

• Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.

  The Journal of antimicrobial chemotherapy 20071001

• Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.

  HIV medicine 20071001

• The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20071001

• Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.

  Cancer research 20071001

• Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

  The Journal of biological chemistry 20070928

• Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.

  Journal of medicinal chemistry 20070906

• Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis.

  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20070901

• Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5).

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

  Antimicrobial agents and chemotherapy 20070901

• Development and evaluation of an immunoassay for the monitoring of the anti-HIV drug amprenavir.

  Journal of immunological methods 20070831

• Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

  Antimicrobial agents and chemotherapy 20070801

• Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070801

• Darunavir: a nonpeptidic antiretroviral protease inhibitor.

  Clinical therapeutics 20070801

• Review of tipranavir in the treatment of drug-resistant HIV.

  Therapeutics and clinical risk management 20070801

• Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.

  AIDS (London, England) 20070711

• Optimal timing and duration of induction therapy for HIV-1 infection.

  PLoS computational biology 20070701

• Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.

  The new microbiologica 20070701

• Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.

  AIDS (London, England) 20070619

• A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20070601

• HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.

  Biochemical pharmacology 20070601

• Fosamprenavir calcium plus ritonavir for HIV infection.

  Expert review of anti-infective therapy 20070601

• Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.

  Metabolic syndrome and related disorders 20070601

• Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.

  AIDS (London, England) 20070531

• In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.

  International journal of pharmaceutics 20070524

• HIV protease inhibitors enhance the efficacy of irradiation.

  Cancer research 20070515

• Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

  PLoS computational biology 20070501

• Combining resistance and pharmacology for optimum patient care.

  Current opinion in HIV and AIDS 20070501

• An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.

  Journal of medicinal chemistry 20070322

• High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.

  Journal of pharmaceutical and biomedical analysis 20070312

• Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.

  Journal of molecular modeling 20070201

• A combined empirical and mechanistic codon model.

  Molecular biology and evolution 20070201

• Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

  The Journal of antimicrobial chemotherapy 20070201

• Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.

  AIDS (London, England) 20070111

• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101

• Evaluation of 384-well formatted sample preparation technologies for regulated bioanalysis.

  Rapid communications in mass spectrometry : RCM 20070101

• A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

  PLoS medicine 20070101

• In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions.

  PLoS pathogens 20070101

• AIDS in the Third World: how to stop the HIV infection?

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Anti-HIV drugs.

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.

  BMC infectious diseases 20070101

• Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20070101

• Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.

  Rapid communications in mass spectrometry : RCM 20070101

• Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.

  Antiviral therapy 20070101

• Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

  Antiviral therapy 20070101

• Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005.

  AIDS research and therapy 20070101

• The contribution of peroxynitrite generation in HIV replication in human primary macrophages.

  Retrovirology 20070101

• Medicinal importance of grapefruit juice and its interaction with various drugs.

  Nutrition journal 20070101

• Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.

  Cost effectiveness and resource allocation : C/E 20070101

• Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.

  Current medicinal chemistry 20070101

• P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.

  Biochemistry 20061226

• Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.

  Journal of medicinal chemistry 20061214

• HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.

  American journal of physiology. Gastrointestinal and liver physiology 20061201

• HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.

  Neoplasia (New York, N.Y.) 20061101

• New, potent P1/P2-morpholinone-based HIV-protease inhibitors.

  Bioorganic & medicinal chemistry letters 20061001

• A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.

  British journal of cancer 20060918

• Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.

  Anti-cancer drugs 20060901

• Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20060824

• Predictors for lower quality of life in the HAART era among HIV-infected men.

  Journal of acquired immune deficiency syndromes (1999) 20060801

• Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring.

  Therapeutic drug monitoring 20060801

• A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study.

  PLoS clinical trials 20060701

• Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.

  Antiviral research 20060601

• Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model.

  Biophysical journal 20060601

• Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

  Biochemistry 20060502

• Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.

  The Journal of general virology 20060501

• Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.

  The Journal of general virology 20060501

• Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.

  Journal of acquired immune deficiency syndromes (1999) 20060501

• Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.

  Transplantation proceedings 20060501

• [Effects of various HIV protease inhibitors on function of rat insulinoma cells].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060501

• Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

  AIDS (London, England) 20060424

• Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

  Bioorganic & medicinal chemistry letters 20060401

• Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20060401

• Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.

  Pharmacotherapy 20060401

• Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060401

• MDR- and CYP3A4-mediated drug-herbal interactions.

  Life sciences 20060327

• In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

  Antimicrobial agents and chemotherapy 20060301

• A monolithic-phase based on-line extraction approach for determination of pharmaceutical components in human plasma by HPLC-MS/MS and a comparison with liquid-liquid extraction.

  Journal of pharmaceutical and biomedical analysis 20060224

• Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060217

• LC-MS/MS determination of the HIV-1 protease inhibitor indinavir in brain and testis of mice.

  Journal of pharmaceutical and biomedical analysis 20060213

• Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir.

  Journal of pharmaceutical sciences 20060201

• Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration.

  Therapeutic drug monitoring 20060201

• Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.

  The Journal of biological chemistry 20060120

• High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

  AIDS (London, England) 20060102

• Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.

  AIDS (London, England) 20060102

• Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography.

  Biomedical chromatography : BMC 20060101

• Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20060101

• Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

  Basic & clinical pharmacology & toxicology 20060101

• Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

  Clinical pharmacokinetics 20060101

• Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma.

  Clinical chemistry and laboratory medicine 20060101

• DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.

  BMC infectious diseases 20060101

• Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.

  Antiviral therapy 20060101

• Fosamprenavir: drug development for adherence.

  The Annals of pharmacotherapy 20060101

• A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection.

  Rapid communications in mass spectrometry : RCM 20060101

• Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy.

  HIV clinical trials 20060101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20060101

• Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.

  Antiviral therapy 20060101

• Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.

  ChemMedChem 20060101

• Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.

  HIV clinical trials 20060101

• Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin.

  Antiviral chemistry & chemotherapy 20060101

• Drug interactions. Amprenavir with low-dose ritonavir.

  TreatmentUpdate 20060101

• Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.

  Antiviral therapy 20060101

• Molecular drug targets and structure based drug design: A holistic approach.

  Bioinformation 20060101

• Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051227

• Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.

  Journal of acquired immune deficiency syndromes (1999) 20051201

• Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

  Therapeutics and clinical risk management 20051201

• Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.

  Antimicrobial agents and chemotherapy 20051101

• Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization.

  Journal of medicinal chemistry 20051020

• MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells.

  AIDS (London, England) 20051014

• Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20051001

• The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km.

  Pharmaceutical research 20051001

• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  Current drug metabolism 20051001

• HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.

  Cancer research 20050915

• The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals.

  AIDS (London, England) 20050902

• A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.

  Journal of virological methods 20050901

• Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.

  Journal of acquired immune deficiency syndromes (1999) 20050901

• Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050815

• Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050801

• Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.

  Bioorganic & medicinal chemistry letters 20050801

• Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.

  European journal of clinical pharmacology 20050801

• Acanthosis nigricans as an adverse effect of highly active antiretroviral therapy in an adolescent girl with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20050801

• Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort.

  AIDS research and human retroviruses 20050801

• HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715

• Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma.

  Biological & pharmaceutical bulletin 20050701

• Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20050601

• Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma.

  Therapeutic drug monitoring 20050601

• TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

  Antimicrobial agents and chemotherapy 20050601

• Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay.

  Antimicrobial agents and chemotherapy 20050601

• A long-term survival case of small cell lung cancer in an HIV-infected patient.

  Japanese journal of clinical oncology 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050525

• Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.

  AIDS (London, England) 20050520

• Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

  Journal of medicinal chemistry 20050519

• Oximinoarylsulfonamides as potent HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050502

• Emerging anti-HIV drugs.

  Expert opinion on emerging drugs 20050501

• Stimulation of intracellular Ca2+ elevation in neutrophils by thiol-oxidizing phenylarsine oxide.

  Biochemical pharmacology 20050415

• Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20050401

• Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

  PLoS medicine 20050401

• Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics.

  AIDS (London, England) 20050325

• Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.

  Journal of medicinal chemistry 20050324

• Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

  Journal of medicinal chemistry 20050324

• Genotype dependent QSAR for HIV-1 protease inhibition.

  Journal of medicinal chemistry 20050324

• Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.

  Bioorganic & medicinal chemistry letters 20050301

• Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

  Therapeutics and clinical risk management 20050301

• Mechanism-based inactivation of CYP3A by HIV protease inhibitors.

  The Journal of pharmacology and experimental therapeutics 20050201

• Mycotic brain abscess caused by opportunistic reptile pathogen.

  Emerging infectious diseases 20050201

• Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

  AIDS (London, England) 20050128

• Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines.

  The Journal of biological chemistry 20050121

• Optimization of pyrrolidinone based HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050103

• The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

  Biophysical journal 20050101

• Molecular strategies to inhibit HIV-1 replication.

  Retrovirology 20050101

• Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

  Drugs 20050101

• Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

  BMC infectious diseases 20050101

• Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.

  HIV clinical trials 20050101

• Drug-drug interactions and the pharmacotherapy of HIV infection.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101

• Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20050101

• Scutellaria baicalensis decreases ritonavir-induced nausea.

  AIDS research and therapy 20050101

• Discovery of next generation inhibitors of HIV protease.

  Current topics in medicinal chemistry 20050101

• Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

  Journal of the International AIDS Society 20050101

• Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.

  The Journal of endocrinology 20041201

• Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

  Antiviral therapy 20041201

• Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy.

  Journal of chemotherapy (Florence, Italy) 20041201

• Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.

  Memorias do Instituto Oswaldo Cruz 20041201

• Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.

  Journal of medicinal chemistry 20041118

• Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.

  Biochemistry 20041116

• CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.

  AIDS (London, England) 20041105

• Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101

• Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20041101

• Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.

  Journal of clinical pharmacology 20041101

• Pharmacokinetics of Telzir (fosamprenavir).

  Journal of HIV therapy 20041101

• Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015

• Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors.

  Therapeutic drug monitoring 20041001

• Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.

  Antimicrobial agents and chemotherapy 20041001

• Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

  AIDS (London, England) 20040924

• Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.

  Journal of medical virology 20040901

• Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.

  Journal of medical virology 20040901

• Fosamprenavir: advancing HIV protease inhibitor treatment options.

  Expert opinion on pharmacotherapy 20040901

• Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.

  HIV medicine 20040901

• Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.

  Pharmacotherapy 20040901

• A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815

• The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20040801

• Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier.

  Journal of pharmaceutical sciences 20040801

• HIV and drug allergy.

  Immunology and allergy clinics of North America 20040801

• Resistance to HIV protease inhibitors: mechanisms and clinical consequences.

  Current drug metabolism 20040801

• Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.

  American journal of obstetrics and gynecology 20040801

• Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

  Antiviral therapy 20040801

• SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

  AIDS (London, England) 20040723

• New approaches to the industrial synthesis of HIV protease inhibitors.

  Organic & biomolecular chemistry 20040721

• Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.

  AIDS (London, England) 20040702

• HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20040701

• Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20040701

• The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.

  Drug metabolism and disposition: the biological fate of chemicals 20040701

• Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.

  HIV medicine 20040701

• A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

  HIV medicine 20040701

• High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615

• Antiviral drugs in current clinical use.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601

• The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

  Antiviral therapy 20040601

• Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.

  Antiviral therapy 20040601

• Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.

  The Journal of infectious diseases 20040515

• HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040501

• High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.

  Journal of molecular biology 20040423

• Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.

  AIDS (London, England) 20040409

• Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors.

  The Journal of organic chemistry 20040402

• Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.

  Clinical pharmacology and therapeutics 20040401

• Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.

  Antiviral therapy 20040401

• Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.

  The Journal of antimicrobial chemotherapy 20040301

• Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.

  Antimicrobial agents and chemotherapy 20040301

• In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.

  Pharmaceutical research 20040301

• Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.

  Bioorganic & medicinal chemistry letters 20040223

• Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus.

  Antiviral research 20040201

• Antiviral sulfonamide derivatives.

  Mini reviews in medicinal chemistry 20040201

• Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV.

  Antiviral therapy 20040201

• Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

  Antiviral therapy 20040201

• Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20040102

• Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.

  AIDS (London, England) 20040102

• Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

  Antimicrobial agents and chemotherapy 20040101

• A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir.

  HIV medicine 20040101

• Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis.

  International journal of STD & AIDS 20040101

• Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.

  AIDS patient care and STDs 20040101

• Kinetic and thermodynamic characterization of HIV-1 protease inhibitors.

  Journal of molecular recognition : JMR 20040101

• Peptidomimetic inhibitors of HIV protease.

  Current topics in medicinal chemistry 20040101

• Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.

  Drugs 20040101

• Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.

  Cardiovascular toxicology 20040101

• Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

  Clinical pharmacokinetics 20040101

• Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes).

  Theoretical biology & medical modelling 20040101

• Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.

  AIDS (London, England) 20031205

• Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.

  Biochemistry 20031125

• Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.

  AIDS (London, England) 20031121

• Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031101

• HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.

  The Journal of antimicrobial chemotherapy 20031101

• New patterns of HIV-1 resistance during HAART.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20031101

• Lexiva (fosamprenavir) approved.

  AIDS treatment news 20031031

• Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.

  AIDS (London, England) 20031017

• Modulation of the LDL receptor and LRP levels by HIV protease inhibitors.

  Journal of lipid research 20031001

• Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20031001

• Atazanavir (Reyataz).

  Project Inform perspective 20031001

• Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.

  Statistics in medicine 20030915

• Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.

  Medicinal research reviews 20030901

• Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum.

  The Journal of antimicrobial chemotherapy 20030901

• Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.

  The Journal of antimicrobial chemotherapy 20030901

• Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.

  The Journal of antimicrobial chemotherapy 20030901

• In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.

  Antimicrobial agents and chemotherapy 20030901

• The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells.

  The Journal of endocrinology 20030901

• [Resistance of HIV-1 to antiretroviral drugs in Valencia (Spain): mutations and susceptibility].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20030901

• The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety.

  Bioorganic & medicinal chemistry letters 20030804

• A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

  Antiviral therapy 20030801

• Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.

  Antiviral therapy 20030801

• Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

  The Journal of infectious diseases 20030715

• HIV protease inhibitors acutely impair glucose-stimulated insulin release.

  Diabetes 20030701

• Effects of didanosine formulations on the pharmacokinetics of amprenavir.

  Pharmacotherapy 20030701

• Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20030701

• Rapid enzymatic test for phenotypic HIV protease drug resistance.

  Biological chemistry 20030701

• Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.

  Therapeutic drug monitoring 20030601

• Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

  Therapeutic drug monitoring 20030601

• Comparison of nine resistance interpretation systems for HIV-1 genotyping.

  Antiviral therapy 20030601

• Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525

• Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.

  AIDS (London, England) 20030523

• Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.

  AIDS (London, England) 20030502

• Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance.

  AIDS (London, England) 20030502

• Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants.

  Antiviral research 20030501

• Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425

• Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.

  Journal of medicinal chemistry 20030424

• Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20030415

• Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

  Antimicrobial agents and chemotherapy 20030401

• HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

  Antiviral therapy 20030401

• Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation.

  Drug metabolism and disposition: the biological fate of chemicals 20030301

• Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

  Pediatrics 20030301

• Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans.

  Journal of medical microbiology 20030301

• Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.

  Journal of acquired immune deficiency syndromes (1999) 20030301

• Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.

  European journal of medical research 20030221

• Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205

• Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction.

  The Annals of pharmacotherapy 20030201

• Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.

  Biological & pharmaceutical bulletin 20030201

• Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Journal of mass spectrometry : JMS 20030201

• Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma.

  Journal of chromatographic science 20030201

• Practical applications of viral fitness in clinical practice.

  Current opinion in infectious diseases 20030201

• Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115

• Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.

  British journal of clinical pharmacology 20030101

• Severe cutaneous reactions associated with the use of human immunodeficiency virus medications.

  Acta dermato-venereologica 20030101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20030101

• Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

  BMC infectious diseases 20030101

• Prodrugs of HIV protease inhibitors.

  Current pharmaceutical design 20030101

• The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells.

  In vitro cellular & developmental biology. Animal 20030101

• Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

  HIV clinical trials 20030101

• Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.

  Clinical pharmacology and therapeutics 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• New anti-HIV agents and targets.

  Medicinal research reviews 20021101

• Can HIV infection be treated successfully with a once-daily regimen?

  The AIDS reader 20021101

• Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.

  Journal of pharmaceutical and biomedical analysis 20021015

• Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• FDA notifications. Agenerase product label changed.

  AIDS alert 20021001

• In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome.

  Mitochondrion 20021001

• Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.

  AIDS research and human retroviruses 20020920

• Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020915

• The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

  AIDS (London, England) 20020906

• Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS.

  International journal of STD & AIDS 20020901

• Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020815

• Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.

  Protein science : a publication of the Protein Society 20020801

• Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20020801

• Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.

  Journal of clinical pharmacology 20020801

• Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.

  European journal of biochemistry 20020801

• Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.

  Clinical pharmacology and therapeutics 20020801

• New developments in anti-HIV chemotherapy.

  Biochimica et biophysica acta 20020718

• Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.

  Journal of medicinal chemistry 20020718

• Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715

• The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).

  The Journal of infectious diseases 20020715

• Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

  JAMA 20020710

• In vitro antiviral interaction of lopinavir with other protease inhibitors.

  Antimicrobial agents and chemotherapy 20020701

• Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure.

  Journal of medical virology 20020701

• Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry.

  Biomedical chromatography : BMC 20020601

• High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.

  Therapeutic drug monitoring 20020601

• Gateways to Clinical Trials. June 2002.

  Methods and findings in experimental and clinical pharmacology 20020601

• Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

  The Journal of biological chemistry 20020531

• Therapeutic vaccination in primary HIV infection, the Quest trial.

  Vaccine 20020506

• Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

  AIDS (London, England) 20020503

• Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020501

• Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.

  Therapeutic drug monitoring 20020401

• New dosing regimen approved.

  AIDS patient care and STDs 20020401

• Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.

  AIDS (London, England) 20020329

• Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20020329

• The utility of inhibitory quotients in determining the relative potency of protease inhibitors.

  AIDS (London, England) 20020329

• Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.

  AIDS (London, England) 20020308

• FDA approves new dosing for amprenavir and ritonavir combination.

  AIDS treatment news 20020308

• Efavirenz-induced skin eruption and successful desensitization.

  The Annals of pharmacotherapy 20020301

• Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.

  Journal of pharmaceutical sciences 20020301

• Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.

  The Pediatric infectious disease journal 20020301

• Lipodystrophy update.

  Project Inform perspective 20020301

• Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.

  Current opinion in investigational drugs (London, England : 2000) 20020301

• Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.

  The Journal of biological chemistry 20020222

• HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.

  AIDS (London, England) 20020215

• A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

  Journal of virology 20020201

• In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

  The Journal of pharmacy and pharmacology 20020201

• Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?

  AIDS (London, England) 20020125

• Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020125

• [Advances in the domain of HIV].

  Presse medicale (Paris, France : 1983) 20020119

• Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.

  Journal of medicinal chemistry 20020117

• Clinical pharmacology and pharmacokinetics of amprenavir.

  The Annals of pharmacotherapy 20020101

• Central nervous system toxicity and amprenavir oral solution.

  The Annals of pharmacotherapy 20020101

• Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.

  Arzneimittel-Forschung 20020101

• Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

  HIV clinical trials 20020101

• Retroviral proteases.

  Genome biology 20020101

• Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.

  Antiviral chemistry & chemotherapy 20020101

• Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.

  Antiviral chemistry & chemotherapy 20020101

• [Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography ].

  Therapie 20020101

• Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.

  HIV clinical trials 20020101

• [A novel anti-HIV agent--agenerase].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20020101

• Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011215

• Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection.

  Therapeutic drug monitoring 20011201

• Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

  Antiviral therapy 20011201

• Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations.

  Antiviral therapy 20011201

• Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.

  AIDS (London, England) 20011123

• Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.

  The Journal of infectious diseases 20011115

• New developments in anti-HIV chemotherapy.

  Current medicinal chemistry 20011101

• DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.

  Antimicrobial agents and chemotherapy 20011101

• From amprenavir to GW433908.

  Journal of HIV therapy 20011101

• Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.

  Therapeutic drug monitoring 20011001

• Effectors of HIV-1 protease peptidolytic activity.

  Biochemistry 20010918

• Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.

  Antiviral research 20010901

• In vitro activity of amprenavir against Pneumocystis carinii.

  International journal of antimicrobial agents 20010901

• Antiviral drugs: current state of the art.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801

• Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.

  Therapeutic drug monitoring 20010801

• HIV and drug allergy.

  Current opinion in allergy and clinical immunology 20010801

• Synthesis of a chiral aziridine derivative as a versatile intermediate for HIV protease inhibitors.

  Organic letters 20010726

• High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.

  Journal of chromatography. B, Biomedical sciences and applications 20010715

• Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapy.

  Journal of chromatography. A 20010713

• Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.

  AIDS patient care and STDs 20010701

• Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010615

• Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.

  Antiviral therapy 20010601

• A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.

  Antiviral therapy 20010601

• Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance.

  Prescrire international 20010601

• Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.

  AIDS (London, England) 20010525

• Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010505

• Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20010501

• Drifting agenda for federal treatment research.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20010501

• Resistant to everything.

  AIDS clinical care 20010501

• Liquid chromatographic-tandem mass spectrometric determination of amprenavir (agenerase) in serum/plasma of human immunodeficiency virus type-1 infected patients receiving combination antiretroviral therapy.

  Journal of chromatography. A 20010420

• A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• [Determining resistance in HIV therapy. Careful interpretation only].

  MMW Fortschritte der Medizin 20010402

• Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.

  Journal of clinical pharmacology 20010401

• Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20010401

• Principles and practice of HIV-protease inhibitor pharmacoenhancement.

  HIV medicine 20010401

• Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.

  AIDS (London, England) 20010330

• Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

  AIDS (London, England) 20010309

• Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.

  The Journal of infectious diseases 20010301

• Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.

  The Journal of infectious diseases 20010301

• Phase III trials for new PI.

  AIDS patient care and STDs 20010301

• Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.

  Clinical therapeutics 20010301

• Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.

  Drug metabolism and disposition: the biological fate of chemicals 20010201

• Safety profile and tolerability of amprenavir in patients enrolled in an early access program.

  Clinical therapeutics 20010201

• [Resistance to protease inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20010201

• [Pharmacological study and clinical effect of HIV protease inhibitor amprenavir].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010101

• [Simultaneous quantitative determination of amprenavir and indinavir in human plasma by high-performance liquid chromatography].

  Annales de biologie clinique 20010101

• Structure-based design of non-peptide HIV protease inhibitors.

  Farmaco (Societa chimica italiana : 1989) 20010101

• New developments in anti-HIV chemotherapy.

  Farmaco (Societa chimica italiana : 1989) 20010101

• [Drug interactions with antiretroviral agents].

  Therapie 20010101

• Development of HIV protease inhibitors: a survey.

  Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20010101

• Amping amprenavir with ritonavir.

  TreatmentUpdate 20010101

• Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes.

  Antiviral chemistry & chemotherapy 20010101

• Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.

  Clinical laboratory 20010101

• Inhibition of HIV-1 protease by a boron-modified polypeptide.

  Biochemical pharmacology 20001001

• Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.

  Journal of medicinal chemistry 20000921

• In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.

  Antimicrobial agents and chemotherapy 20000901

• BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

  Antimicrobial agents and chemotherapy 20000801

• Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.

  Journal of virology 20000801

• Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.

  Bioorganic & medicinal chemistry letters 20000605

• A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.

  Journal of virology 20000501

• 2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors.

  Journal of medicinal chemistry 20000323

• Protease inhibitors: current status and future prospects.

  Journal of medicinal chemistry 20000210

• Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 19981215

• Design and synthesis of novel conformationally restricted HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 19981215

• Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.

  Biochemistry 19981027

• Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

  Virology 19981025

• Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

  Antimicrobial agents and chemotherapy 19981001

• Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.

  Chemistry & biology 19981001

• Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

  Bioorganic & medicinal chemistry letters 19980317

• In vitro selection and characterization of VX-478 resistant HIV-1 variants.

  Advances in experimental medicine and biology 19980101

• Four new antiretroviral medications will soon offer more options to HIV patients.

  Faculty notes (New Orleans, La.) 19980101

• Nonsymmetrically substituted cyclic urea HIV protease inhibitors.

  Journal of medicinal chemistry 19971205

• Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives.

  Antimicrobial agents and chemotherapy 19970601

• In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.

  The Journal of infectious diseases 19970501

• Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.

  Journal of medicinal chemistry 19970117

• Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.

  The Journal of biological chemistry 19961213

• Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.

  Journal of virology 19961201

• HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.

  Journal of medicinal chemistry 19961011

• In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.

  Antiviral research 19960101

• Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.

  The Journal of infectious diseases 19951101

• In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.

  Journal of virology 19950901

• In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

  Nature 19950406